714 related articles for article (PubMed ID: 27385177)
61. Drugs and hepatic transporters: A review.
Jetter A; Kullak-Ublick GA
Pharmacol Res; 2020 Apr; 154():104234. PubMed ID: 31004787
[TBL] [Abstract][Full Text] [Related]
62. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.
Liao M; Raczynski AR; Chen M; Chuang BC; Zhu Q; Shipman R; Morrison J; Lee D; Lee FW; Balani SK; Xia CQ
Drug Metab Dispos; 2010 Sep; 38(9):1612-22. PubMed ID: 20516252
[TBL] [Abstract][Full Text] [Related]
63. A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation.
Kumar V; Salphati L; Hop CECA; Xiao G; Lai Y; Mathias A; Chu X; Humphreys WG; Liao M; Heyward S; Unadkat JD
Drug Metab Dispos; 2019 Apr; 47(4):350-357. PubMed ID: 30622164
[TBL] [Abstract][Full Text] [Related]
64. Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.
Choi MK; Kwon M; Ahn JH; Kim NJ; Bae MA; Song IS
Biopharm Drug Dispos; 2014 Apr; 35(3):183-94. PubMed ID: 24285344
[TBL] [Abstract][Full Text] [Related]
65. Uptake and efflux transporters for conjugates in human hepatocytes.
Keppler D
Methods Enzymol; 2005; 400():531-42. PubMed ID: 16399368
[TBL] [Abstract][Full Text] [Related]
66. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.
Durmus S; Naik J; Buil L; Wagenaar E; van Tellingen O; Schinkel AH
Int J Cancer; 2014 Oct; 135(7):1700-10. PubMed ID: 24554572
[TBL] [Abstract][Full Text] [Related]
67. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites.
Zamek-Gliszczynski MJ; Hoffmaster KA; Nezasa K; Tallman MN; Brouwer KL
Eur J Pharm Sci; 2006 Apr; 27(5):447-86. PubMed ID: 16472997
[TBL] [Abstract][Full Text] [Related]
68. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.
Shitara Y
Drug Metab Pharmacokinet; 2011 Jun; 26(3):220-7. PubMed ID: 21297316
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Veiga-Matos J; Remião F; Motales A
J Pharm Pharm Sci; 2020; 23():333-356. PubMed ID: 32997956
[TBL] [Abstract][Full Text] [Related]
70. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Rodrigues AD; Lai Y; Shen H; Varma MVS; Rowland A; Oswald S
Drug Metab Dispos; 2020 Mar; 48(3):205-216. PubMed ID: 31879282
[TBL] [Abstract][Full Text] [Related]
71. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
Keppler D
Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
[TBL] [Abstract][Full Text] [Related]
72. The complexities of hepatic drug transport: current knowledge and emerging concepts.
Chandra P; Brouwer KL
Pharm Res; 2004 May; 21(5):719-35. PubMed ID: 15180326
[TBL] [Abstract][Full Text] [Related]
73. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
[TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.
Kusuhara H; Sugiyama Y
Drug Metab Rev; 2010 Aug; 42(3):539-50. PubMed ID: 20175646
[TBL] [Abstract][Full Text] [Related]
75. Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.
Kimoto E; Mathialagan S; Tylaska L; Niosi M; Lin J; Carlo AA; Tess DA; Varma MVS
J Pharmacol Exp Ther; 2018 Nov; 367(2):322-334. PubMed ID: 30135178
[TBL] [Abstract][Full Text] [Related]
76. Role of OATP transporters in the disposition of drugs.
Niemi M
Pharmacogenomics; 2007 Jul; 8(7):787-802. PubMed ID: 18240907
[TBL] [Abstract][Full Text] [Related]
77. MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study.
Holmstock N; Oorts M; Snoeys J; Annaert P
Drug Metab Dispos; 2018 May; 46(5):697-703. PubMed ID: 29523599
[TBL] [Abstract][Full Text] [Related]
78. Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes.
Roggenbeck BA; Carew MW; Charrois GJ; Douglas DN; Kneteman NM; Lu X; Le XC; Leslie EM
Toxicol Sci; 2015 Jun; 145(2):307-20. PubMed ID: 25752797
[TBL] [Abstract][Full Text] [Related]
79. Recommendation to Exclude Bile-Duct-Cannulated Rats with Hyperbilirubinemia for Proper Conduct of Biliary Drug Excretion Studies.
Kato K; Hasegawa Y; Iwata K; Ichikawa T; Yahara T; Tsuji S; Sugiura M; Yamaguchi J
Drug Metab Dispos; 2016 Aug; 44(8):1180-3. PubMed ID: 27208382
[TBL] [Abstract][Full Text] [Related]
80. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.
Perri D; Ito S; Rowsell V; Shear NH
Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
